Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
(2023)
Journal Article
Williams, C. J. M., Elliott, F., Sapanara, N., Aghaei, F., Zhang, L., Muranyi, A., Yan, D., Bai, I., Zhao, Z., Shires, M., Wood, H. M., Richman, S. D., Hemmings, G., Hale, M., Bottomley, D., Galvin, L., Cartlidge, C., Dance, S., Bacon, C. M., Mansfield, L., …Quirke, P. (2023). Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer. Clinical Cancer Research, 29(20), 4153-4165. https://doi.org/10.1158/1078-0432.CCR-23-0859
Purpose: High tumor production of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), predicted benefit from anti-EGFR therapy for metastatic colorectal cancer (mCRC) in a retrospective analysis of clinical trial data. Here, AREG/EREG IHC wa... Read More about Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.